Screener
Intellia Therapeutics NTLA EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
FAQ
- What is Intellia Therapeutics's EPS (diluted)?
- Intellia Therapeutics (NTLA) reported EPS (diluted) of -$0.80 in Q2 2026.
- How has Intellia Therapeutics's EPS (diluted) changed year-over-year?
- Intellia Therapeutics's EPS (diluted) increased by 18.4% year-over-year, from -$0.98 to -$0.80.
- What is the long-term trend for Intellia Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Intellia Therapeutics's EPS (diluted) has grown at a 0.3% compound annual growth rate (CAGR), from -$3.77 to -$3.82.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Intellia Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude